Daniel J Simmons, Stephen J Valerio, Darren S Thomas, Marcus J Healey, Zhuoxin Jiang, Jesica M Levingston Mac Leod, Yian Lin, Janvi Sah
INTRODUCTION: Systemic therapies have been associated with clinically significant events (CSEs) in patients with unresectable hepatocellular carcinoma (uHCC). We evaluated the incidence of CSEs (bleeding, clotting, encephalopathy, and portal hypertension), and their impact on healthcare resource utilization (HCRU) and costs, in patients with uHCC treated with first-line (1L) atezolizumab plus bevacizumab (A + B), lenvatinib (LEN), or sorafenib (SOR) in the USA. METHODS: A retrospective cohort study was performed using medical/pharmacy claims from Optum® Clinformatics® Data Mart...
March 5, 2024: Advances in Therapy